Compare LULU & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LULU | VTRS |
|---|---|---|
| Founded | 1998 | 1961 |
| Country | Canada | United States |
| Employees | N/A | 30000 |
| Industry | Apparel | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8B | 17.2B |
| IPO Year | 2007 | 2019 |
| Metric | LULU | VTRS |
|---|---|---|
| Price | $162.29 | $13.86 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 25 | 4 |
| Target Price | ★ $190.26 | $13.50 |
| AVG Volume (30 Days) | 2.6M | ★ 7.2M |
| Earning Date | 06-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 3.45% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 13.26 | N/A |
| Revenue | $11,102,600,000.00 | ★ $14,299,900,000.00 |
| Revenue This Year | $5.52 | $4.41 |
| Revenue Next Year | $4.68 | $1.96 |
| P/E Ratio | $12.08 | ★ N/A |
| Revenue Growth | ★ 4.86 | N/A |
| 52 Week Low | $143.96 | $7.39 |
| 52 Week High | $340.25 | $16.47 |
| Indicator | LULU | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 49.62 | 52.37 |
| Support Level | $159.83 | $12.90 |
| Resistance Level | $171.31 | $16.38 |
| Average True Range (ATR) | 6.08 | 0.31 |
| MACD | 1.63 | 0.10 |
| Stochastic Oscillator | 74.11 | 86.67 |
Lululemon Athletica designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. The company offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. Lululemon also sells fitness accessories, such as bags, yoga mats, and equipment. It sells its products through digital channels, a small number of wholesale partners, more than 800 company-owned stores in about two dozen countries in North America, Asia, and Western Europe, and about 45 franchised locations in the Middle East and Europe. The company was founded in 1998 and is based in Vancouver, Canada.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.